AR132295A1 - Inhibidores de kras - Google Patents
Inhibidores de krasInfo
- Publication number
- AR132295A1 AR132295A1 ARP240100807A ARP240100807A AR132295A1 AR 132295 A1 AR132295 A1 AR 132295A1 AR P240100807 A ARP240100807 A AR P240100807A AR P240100807 A ARP240100807 A AR P240100807A AR 132295 A1 AR132295 A1 AR 132295A1
- Authority
- AR
- Argentina
- Prior art keywords
- kras inhibitors
- pharmaceutically acceptable
- acceptable salts
- kras
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382315 | 2023-03-31 | ||
| EP23382531 | 2023-06-02 | ||
| EP23382857 | 2023-08-18 | ||
| EP23382985 | 2023-09-27 | ||
| EP24382267 | 2024-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132295A1 true AR132295A1 (es) | 2025-06-11 |
Family
ID=90826251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100807A AR132295A1 (es) | 2023-03-31 | 2024-04-03 | Inhibidores de kras |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240368193A1 (enExample) |
| JP (2) | JP7669556B2 (enExample) |
| KR (1) | KR20250163395A (enExample) |
| CN (1) | CN121002032A (enExample) |
| AR (1) | AR132295A1 (enExample) |
| AU (1) | AU2024241889A1 (enExample) |
| CO (1) | CO2025013134A2 (enExample) |
| DO (1) | DOP2025000245A (enExample) |
| IL (1) | IL323362A (enExample) |
| MX (1) | MX2025011449A (enExample) |
| WO (1) | WO2024206766A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4655073A2 (en) | 2023-01-26 | 2025-12-03 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535880A (zh) * | 2023-10-30 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017011920A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202033518A (zh) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| PL3886991T3 (pl) | 2019-12-11 | 2022-11-21 | Eli Lilly And Company | Inhibitory KRAS G12C |
| WO2022037631A1 (zh) | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| TWI880049B (zh) | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| CN115611923A (zh) | 2021-07-12 | 2023-01-17 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN117222654A (zh) | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| CN115785199A (zh) | 2021-09-10 | 2023-03-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| AU2023241055A1 (en) * | 2022-03-25 | 2024-10-10 | Eli Lilly And Company | Kras inhibitors |
-
2024
- 2024-03-29 AU AU2024241889A patent/AU2024241889A1/en active Pending
- 2024-03-29 WO PCT/US2024/022154 patent/WO2024206766A1/en active Pending
- 2024-03-29 JP JP2024055240A patent/JP7669556B2/ja active Active
- 2024-03-29 US US18/621,388 patent/US20240368193A1/en active Pending
- 2024-03-29 CN CN202480023688.7A patent/CN121002032A/zh active Pending
- 2024-03-29 KR KR1020257035985A patent/KR20250163395A/ko active Pending
- 2024-04-03 AR ARP240100807A patent/AR132295A1/es unknown
-
2025
- 2025-04-16 JP JP2025067243A patent/JP2025111535A/ja active Pending
- 2025-09-14 IL IL323362A patent/IL323362A/en unknown
- 2025-09-25 CO CONC2025/0013134A patent/CO2025013134A2/es unknown
- 2025-09-26 MX MX2025011449A patent/MX2025011449A/es unknown
- 2025-09-29 DO DO2025000245A patent/DOP2025000245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024241889A1 (en) | 2025-09-25 |
| IL323362A (en) | 2025-11-01 |
| MX2025011449A (es) | 2025-11-03 |
| KR20250163395A (ko) | 2025-11-20 |
| DOP2025000245A (es) | 2025-11-16 |
| JP2024146897A (ja) | 2024-10-15 |
| CN121002032A (zh) | 2025-11-21 |
| US20240368193A1 (en) | 2024-11-07 |
| JP2025111535A (ja) | 2025-07-30 |
| JP7669556B2 (ja) | 2025-04-28 |
| CO2025013134A2 (es) | 2025-10-09 |
| TW202506688A (zh) | 2025-02-16 |
| WO2024206766A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR132295A1 (es) | Inhibidores de kras | |
| AR132294A1 (es) | Inhibidores de kras | |
| CL2024002874A1 (es) | Inhibidores de kras | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2022007969A (es) | Inhibidores de egfr. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| AR133985A1 (es) | Inhibidores de kras | |
| CY1124086T1 (el) | Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης | |
| MX2025008591A (es) | Inhibidores de cdk | |
| CL2024000067A1 (es) | Compuestos antivirales | |
| MX2024015363A (es) | Compuestos de haloalquinilo para el tratamiento de cáncer | |
| MX2020007392A (es) | Compuestos de benzamida. | |
| CL2021003202A1 (es) | Compuestos de pirrolidina | |
| AR130425A1 (es) | Inhibidores de kras(g12d) | |
| MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| CR20240203A (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| AR119557A1 (es) | Compuestos de 7,8-dihidro-4h-pirazolo[4,3-c]azepina-6-ona | |
| AR128894A1 (es) | Inhibidores de kras | |
| MX2024009441A (es) | Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). | |
| AR131945A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2024000022A (es) | Compuestos terapeuticos. | |
| MX2024012198A (es) | Compuestos y metodos para tratar canceres |